 |
|
Senile Systemic Amyloidosis Presenting With Heart Failure
A Comparison With Light Chain–Associated Amyloidosis
Belinda Ng, MD;
Lawreen H. Connors, PhD;
Ravin Davidoff, MB, BCh;
Martha Skinner, MD;
Rodney H. Falk, MD
Arch Intern Med. 2005;165:1425-1429.
Background Small deposits of amyloid are often found in the hearts of elderly patients. However, extensive deposition of transthyretin-derived amyloid fibrils in the heart (senile systemic amyloidosis [SSA]) can cause heart failure. The clinical features of SSA that involve the heart are ill defined, and the condition may be overlooked as a cause of heart failure. We sought to better define the clinical, echocardiographic, and electrocardiographic features of cardiac involvement in SSA and to compare them with the findings in patients with light chain–associated (AL) amyloidosis that affects the heart.
Methods Eighteen consecutive patients with SSA and heart failure evaluated at a tertiary referral center for the diagnosis and treatment of amyloidosis were compared with 18 randomly selected patients with AL amyloidosis that involved the heart. All patients underwent a complete clinical and biochemical evaluation. Echocardiograms and electrocardiograms were interpreted by blinded investigators.
Results Patients with SSA were older than those with AL amyloidosis and were all male. Proteinuria (protein output of >1 g per 24 hours) was common in AL amyloidosis but was not present in SSA. Left ventricular wall thickness was greater in patients with SSA than those with AL amyloidosis, but despite thicker walls and older age, the severity of heart failure was less in the SSA group and the median survival was much longer (75 vs 11 months; P = .003).
Conclusions Senile systemic amyloidosis is a disorder of elderly men and is characterized by amyloidosis clinically limited to the heart. In contrast to the rapid progression of heart failure in AL amyloidosis, SSA results in slowly progressive heart failure. The difference in survival, despite evidence of more myocardial disease in the senile group, suggests that heart failure in AL amyloidosis may have a toxic component, possibly related to the circulating monoclonal light chain.
Author Affiliations: Amyloidosis Treatment and Research Program (Drs Ng, Connors, Skinner, and Falk), Sections of Cardiology (Drs Ng, Davidoff, and Falk) and Arthritis (Dr Skinner), Departments of Medicine and Biochemistry (Dr Connors), Boston University School of Medicine, Boston, Mass.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Female Sex as a Possible Protective Factor From Myocardial Involvement in Transthyretin-Related Amyloidoses
Claudio Rapezzi, Enrica Perugini, and Fabrizio Salvi
Arch Intern Med. 2005;165(20):2429.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
How I treat amyloidosis
Comenzo
Blood 2009;114:3147-3157.
ABSTRACT
| FULL TEXT
Systemic Cardiac Amyloidoses: Disease Profiles and Clinical Courses of the 3 Main Types
Rapezzi et al.
Circulation 2009;120:1203-1212.
ABSTRACT
| FULL TEXT
The Modulation of Transthyretin Tetramer Stability by Cysteine 10 Adducts and the Drug Diflunisal: DIRECT ANALYSIS BY FLUORESCENCE-DETECTED ANALYTICAL ULTRACENTRIFUGATION
Kingsbury et al.
J. Biol. Chem. 2008;283:11887-11896.
ABSTRACT
| FULL TEXT
Evaluation and Management of the Cardiac Amyloidosis
Selvanayagam et al.
J Am Coll Cardiol 2007;50:2101-2110.
ABSTRACT
| FULL TEXT
Amyloidosis and the heart: a comprehensive review.
Shah et al.
Arch Intern Med 2006;166:1805-1813.
ABSTRACT
| FULL TEXT
Female Sex as a Possible Protective Factor From Myocardial Involvement in Transthyretin-Related Amyloidoses
Rapezzi et al.
Arch Intern Med 2005;165:2429-2429.
FULL TEXT
Diagnosis and Management of the Cardiac Amyloidoses
Falk
Circulation 2005;112:2047-2060.
FULL TEXT
|
